Baricitinib is a tyrosine-protein kinase JAK2 inhibitor mainly used for rheumatoid arthritis, and among its pharmacological properties it has an antiviral effect on the entry of a virus (Cantini et al., 2020). This evidence concerns the gene JAK2 and rheumatoid arthritis.